Goldman Sachs analyst Rajan Sharma assumed coverage of AstraZeneca’s (AZN) U.S. shares with a Buy rating and $220 price target The firm believes the positive Phase 3 data for IL-33 tozorakimab in COPD “significantly changes” the setup for the shares through 2026. AstraZeneca’s catalyst path for the remainder of 2026 “has been meaningfully reduced,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca Reports Strong Liver Cancer Results for Imfinzi–Imjudo Combo in EMERALD-3 Trial
- AstraZeneca Updates Total Voting Rights and Admits Additional Shares for Employee Schemes
- AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
- Trump Trade: U.S. not pulling assets from Strait of Hormuz yet
- AstraZeneca announces results of 3 trials of efzimfotase alfa